Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 15;9:537. doi: 10.3389/fphys.2018.00537

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Fazakas, Nagaraj, Zabini, Végh, Marsh, Wilhelm, Krizbai, Olschewski, Olschewski and Bálint.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Rho-kinase inhibition ameliorates dasatinib-induced elevation of pulmonary artery pressure, but not lung weight changes/edema formation. Isolated perfused rat lungs were exposed to dasatinib (100 nM), dasatinib and Y27632 (10 μM) or vehicle (CTRL) for 150 min. Changes in mean pulmonary artery pressure (mPAP) (A) and lung weight (B) were followed in time. (C,D) Charts represent lung weight and mPAP change compared to the 0’ timepoint. Data analysis was done by two-way ANOVA, with Bonferroni’s post hoc test, five animals/group. Values are presented as mean ± SD; ^∗p < 0.05 as compared to control: CTRL, ^#p < 0.05 as compared to Das.